Similar companies
| Company | % of Shares Outstanding | |
|---|---|---|
![]() |
Capricor TherapeuticsCAPR |
34.16% 5.5% |
![]() |
C4 TherapeuticsCCCC |
32.53% 5.8% |
![]() |
Intellia TherapeuticsNTLA |
31.66% 1.5% |
![]() |
OcugenOCGN |
31.58% 5% |
![]() |
Abeona TherapeuticsABEO |
30.1% 2% |
Karyopharm Therapeutics Short Interest Snapshot
Karyopharm Therapeutics (KPTI) has 7,266,973 shares short (32.04% of shares outstanding), up 20.0% from the prior period — shorts are building. The data is biweekly short interest reported to NASDAQ, with a built-in 2-week reporting lag — the same canonical figure short-interest trackers publish.
Recent KPTI Short Interest Settlements
Each row is a biweekly snapshot — the cadence at which short interest is officially reported. The percent column is the change versus the prior settlement.
| Settlement Date | Shares Short | vs Prior | Days to Cover |
|---|---|---|---|
| Oct 15, 2026 | 7,266,973 | 4.84 | |
| Sep 30, 2026 | 6,056,162 | 4.79 | |
| Sep 15, 2026 | 7,865,168 | 5.01 | |
| Aug 31, 2026 | 9,813,744 | 9.35 | |
| Aug 14, 2026 | 9,640,954 | 4.46 | |
| Jul 31, 2026 | 7,555,693 | 2.67 | |
| Jul 15, 2026 | 6,312,305 | 17.13 | |
| Jun 30, 2026 | 6,583,425 | 9.12 |
Is Karyopharm Therapeutics Heavily Shorted?
"Days to cover" is the number of average trading days it would take shorts to buy back their position at recent volume. For KPTI, that’s currently 4.84 days against 1,501,722 shares of average daily volume. Days to cover above 3 is above-average short pressure for a liquid name, though comfortably below classic squeeze territory.
KPTI Short Interest in Context
Short interest is most useful read against the rest of the picture. Heavy shorting that lines up with insider selling and weakening Employee Business Outlook is a different story from heavy shorting with insider buying and a positive AI Score — the same number, very different setups.
The other signals on KPTI right now:
- KPTI AI Score — 52/100
- Employee Business Outlook — 62% positive (positive)
Read together, the picture is mixed — no decisive read from short interest plus the underlying signals. Worth tracking which side moves first.
For the other side of the position, see KPTI insider transactions and congressional trades. For social-side conviction, see KPTI overall sentiment and Reddit mentions.
Karyopharm Therapeutics Short Interest: Frequently Asked Questions
Karyopharm Therapeutics has 7,266,973 shares short — about 32.04% of its shares outstanding as of Oct 15, 2026. This figure is the official biweekly short interest report, which lags the settlement date by about two weeks — the same convention every short-interest tracker uses. (Note: "% of shares outstanding" runs slightly below the "% of float" you may see on MarketBeat or Fintel, since float excludes insider-held and restricted shares.)
At 7,266,973 shares short and 1,501,722 shares of average daily volume, KPTI’s days-to-cover is 4.84. Days to cover above 3 is above-average short pressure for a liquid name, though comfortably below classic squeeze territory.
Short squeezes happen when heavily shorted stocks rally sharply, forcing shorts to buy back at higher prices. The classic warning signs are days-to-cover above ~5, rising short interest, and a catalyst that pushes price up. KPTI’s days-to-cover at 4.84 is below the classic ~5-day threshold. AltIndex tracks short interest alongside insider activity and sentiment — the same number reads very differently depending on what those other signals say.
The biweekly short interest figures come from NASDAQ’s official short interest report — the same source used by MarketBeat, Fintel, and Benzinga. The data is settlement-date-based, published twice a month, and lags about two weeks. For daily short-selling activity (a higher-frequency complement), see the short squeeze tracker.
Sign up and get more insights on Karyopharm Therapeutics.
See Karyopharm Therapeutics’s complete short interest history
Sign up to unlock 1-year and all-time charts for KPTI, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREE




